Personalized Decision Making In Valvular Heart Disease

Overview

About this study

The purpose of this study is Bioprosthetic valve thrombosis (BPVT) can be predicted in a prospective cohort of patients undergoing transcatheter aortic valve replacement (TAVR) Implementation of pharmacogenetics counselling can prevent major clinical bleeds in patients undergoing TAVR

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients with severe aortic valve disease.

  • Scheduled to undergo transcatheter aortic valve replacement (TAVR) at Mayo Clinic for clinical indication.

  • Intended follow-up for TAVR at Mayo Clinic during the first 18 months after TAVR.

  • Willing and able to provide informed consent

 

Exclusion Criteria:

  • Inability to provide informed consent.

  • No IV access possible.

  • Follow-up planned at outside institution.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/1/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Bastiaan Kietselaer

Contact us for the latest status

Contact information:

Structural Heart Disease Research Coordinators

(507) 255-6133

More information

Publications

Publications are currently not available
.
CLS-20597252

Mayo Clinic Footer